RA'ANANA, Israel, April 10,
2024 /PRNewswire/ -- Inspira™ Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or
"Inspira"), a breakthrough medical technology company, together
with Ennocure MedTech Ltd. ("Ennocure"), announced results from
their collaborative development of a proprietary bio-electronic
treatment to prevent associated bloodstream infections in patients
in intensive care units.
Once developed, Inspira plans to integrate the bio-electronic
novel physical stimulation technology, into the INSPIRA™ ART
patient treatment.
The results of the in vitro study showed a 75%
reduction in bacterial growth 4 hours after the application of the
treatment and a 100% reduction within 24 hours. The in vitro study
was carried out at the Hebrew University of
Jerusalem and involved testing bioelectric patches in an in
vitro environment. As part of the in vitro study, bacteria were
cultured and spread on agar in petri dishes. The bioelectric patch
was then applied to the agar plate and activated for a
pre-specified duration. Following the procedure, the agar plates
were transferred to an incubation chamber for 24 hours and
thereafter examined.
This technology is based on the use of electrical pulses that
inhibit bacterial proliferation. This technology may prevent
bacteria from multiplying and spreading by physical means, a
solution that does not require antiseptic and disinfectant agents.
This technology may have certain advantages, including as a
potential effective mitigation solution to certain side effects in
current standard care solutions that use antiseptic agents and
materials, such as allergies. These standard care solutions may
also encounter bacterial resistance and limited efficacy.
The next major research and development milestone in our
collaboration with Ennocure involves conducting tests on an ex
vivo model to evaluate the efficacy of the treatment in
anticipation of the first prospective first-in-human trials.
Dagi-Ben Noon, CEO of Inspira, stated: "By integrating
our technology to adaptatively oxygenate blood directly with
Ennocure's infection prevention solutions, we are potentially
further expanding the benefits of the INSPIRA ART."
Dr. Manuela Hod, CEO of Ennocure, stated: "Our team is
positive that these results show potential applicability of this
technology to combat life-threatening infections."
About Ennocure MedTech Ltd.
Ennocure, is a pioneer in the development of bio-electronic
wound dressing. At the core of the technology is a proprietary
bio-electronic wound dressing designed to prevent bacterial
infections, while providing remote wound monitoring & infection
alerts based on AI-driven therapy.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), designed to rebalance patient oxygen saturation levels. This
technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been
tested or used in humans and has not been approved by any
regulatory entity.
For more information, please visit our corporate website:
https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential benefits
of the Company's products and potential products, the potential
advantages of the bio-electronic treatment, that if developed, the
Company plans to integrate the bio-electronic physical stimulation
technology into the INSPIRA™ ART treatment, that following its
next milestone in its collaboration with Ennocure it hopes that it
would gain authorization to conduct in-human clinical trials and
that it is potentially further expanding the benefits of the
INSPIRA ART. These forward-looking statements and their
implications are based solely on the current expectations of the
Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S.
Securities and Exchange Commission (the "SEC"), which is available
on the SEC's website, http://www.sec.gov
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-and-ennocure-in-vitro-study-results-show-100-prevention-of-bacterial-growth-that-causes-bloodstream-infections-302113107.html
SOURCE Inspira Technologies